Compassionate Eye Foundation/David Oxberry/OJO Images Ltd
UnitedHealth Group (NYSE:UNH) investors have underperformed the S&P 500 (SP500) over the past year, as UNH delivered a 1Y total return of 3.7%. However, it’s still much more impressive than Humana’s (HUM) -27% 1Y total return, as the company suffered a blowout following its recent earnings release, as management offered a significantly lowered 2024 guidance.
Accordingly, UNH wasn’t immune, falling nearly 14% from its late November 2023 highs through its lows last week. As a result, I believe my caution has panned out, as UNH underperformed the market significantly. However, it’s also critical to note that UnitedHealth operates an integrated healthcare model, spanning health insurance, healthcare services, analytics, and a pharmacy benefit manager or PBM. As a result, it helps mitigate the impact from any segment, although UnitedHealthcare is expected to remain a key revenue base driver.
Notwithstanding the recent concerns over the uncertainties emanating from increased utilization in health insurance leading to a higher medical loss ratio, management believes the trends aren’t expected to persist. Accordingly, UnitedHealth highlighted in its Q4 earnings conference that the “recent seasonal activities are not expected to durably affect the outlook for 2024.” Moreover, the company indicated that while utilization increased, affecting its loss ratio, management underscored that “they are positive for healthcare.”
As a result, I believe that it underpins my observation that UnitedHealth’s well-integrated business model is robust enough to mitigate the impact of its health insurance segment, unlike some of its less diversified peers. Moreover, UnitedHealth maintained its confidence in guiding its FY24 loss ratio to “84%, plus or minus 50 basis points,” which doesn’t imply a structural impact. Furthermore, it’s a marked decline from the 85% metric in Q4’23, which exceeded analysts’ estimates “of a lower MLR of 84.1%.”
Consequently, could the recent uncertainty leading to a pullback in UNH over the past week have been overstated? Why? Because UNH is no longer overvalued.
Accordingly, analysts’ estimates align with management’s expectations of its higher-growth Optum-linked businesses in driving growth in the near- and medium-term. Accordingly, Optum Health delivered 34% revenue growth in FY23, while Optum Insight gained 30%. In addition, Optum Rx (UNH’s PBM) posted a 16% topline gain, as these three units outperformed the corporate average growth of 14.6% in 2023. Despite that, the company would likely need to navigate near-term challenges in its health insurance business since it’s expected to be an industry-wide issue. However, its well-diversified business model should help bolster its ability to meet analysts’ estimates over the next two to three years.
Wall Street has penciled in double-digit adjusted EPS growth through FY26. Accordingly, UnitedHealth is projected to deliver an adjusted EPS CAGR of 11.8% from FY23-26. As a result, the growth normalization phase could bottom out in FY24 before potentially inflecting higher. Moreover, UNH’s adjusted EPS multiple has fallen to 18.2x, slightly below its 10Y average of 18.5x. It’s still valued at a marked premium to its healthcare sector (XLV) peers (“D-” valuation grade) and its industry peers’ median (forward adjusted EPS multiple: 13x). However, UNH’s high-quality and resilient earnings growth profile and solid profitability (“A+” profitability grade) suggest that it could weather these near-term challenges resiliently.
UNH price chart (weekly, medium-term) (TradingView)
As seen above, I assessed dip-buyers returning aggressively as they attempted to help UNH bottom out from last week’s steep selloff. While I didn’t glean a bullish reversal price action, which could have provided a more robust signal, the move down was constructive.
In other words, I assessed that the dip-buying support could help UNH bottom out at its pivotal 50-week moving average or MA (blue line), maintaining its medium-term uptrend bias.
While a possible re-test against its August 2023 lows ($472 level) could be in store, UNH’s dip-buying support from its recent capitulation has helped improve its risk/reward markedly since my previous update.
As a result, I have confidence that the recent uncertainty in the market has likely caused weak holders to give up quickly, providing an opportunity for me to turn bullish at the current levels.
Rating: Upgraded to Buy.
Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Please always apply independent thinking and note that the rating is not intended to time a specific entry/exit at the point of writing unless otherwise specified.
I Want To Hear From You
Have constructive commentary to improve our thesis? Spotted a critical gap in our view? Saw something important that we didn’t? Agree or disagree? Comment below with the aim of helping everyone in the community to learn better!
